3rd Annual Psychiatric Drug Discovery & Development

Venue: The Westin Princeton at Forrestal Village

Location: Princeton, New Jersey, United States

Event Date/Time: Jan 31, 2005
Report as Spam

Description

The meeting is the third in the series, and features the most recent advances of the world’s largest pharmaceutical and biotechnology companies and pioneering academic scientists. New approaches and validated targets in CNS discovery will be presented, including glutamatergic and bioaminergic receptor modulation, and the use of gene expression in in vivo pharmacodynamic assays.

Focused on translational efforts in the development of pharmacologic therapies for CNS and psychiatric diseases, 20+ industry and academic leaders present their most recent data and technologies at this annual gathering of the CNS research community.

Featuring:

Novel Approaches: Glutamatergic and Bioaminergic Receptor Modulation
New Targets: CRF-1, PDE10A, and Trace Amines
Neuroimaging: MRI and PET in CNS Drug Development
Brand Case Study: Seroquel ®
Keynotes

Herbert Y Meltzer, M.D.
Bixler Professor of Psychiatry and Pharmacology
Vanderbilt University School of Medicine

Joel E. Kleinman, M.D., Ph.D.
Chief, Section on Neuropathology and
Deputy Chief, CBDB, GCAP, IRP, NIMH, NIH

Bryan Roth Ph.D.,
Director, National Institute of Mental Health Psychoactive Drug Screening Program
Professor of Biochemistry
Case Western Reserve University Medical School

Brand Case Study: Clinical, Regulatory and Commercial Decisions Leading to Seroquel’s Success

Martin Brecher, M.D.
Medical Science Director
AstraZeneca

Faculty Includes:

AstraZeneca
Bristol Myers Squibb
Cypress Bioscience
Eli Lilly
Massachusetts General Hospital
Miicro Inc.
NIH
NIMH
Novace Corporation
Pfizer, Inc
Psychiatric Genomics
Synaptic Pharmaceuticals
University of Colorado
Vanderbilt University
Wyeth Research

Venue

201 Village Boulevard
Princeton
New Jersey
United States
MORE INFO ON THIS VENUE